Want to see KIDS full AI Analyst Report?
KIDS Stock Chart & Stats
$24.50
$0.95(5.03%)
At close: 4:00 PM EDT
$24.50
$0.95(5.03%)
Day’s Range― - ―
52-Week Range$14.42 - $26.74
Previous Close$20.42
Volume117.04K
Average Volume (3M)196.93K
Market Cap
$639.69M
Enterprise Value$518.17
Total Cash (Recent Filing)$45.88M
Total Debt (Recent Filing)$91.59M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding26,109,789
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside12.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$266.98M
Bulls Say, Bears Say
Bulls Say
Specialized Pediatric Focus And Broad Global Product ReachExclusive pediatric specialization and broad hospital coverage create differentiated clinical expertise, surgeon relationships and distribution reach. This positioning can support sustained adoption as the company expands its product portfolio and addresses unmet needs overlooked by adult-focused competitors.
Strong Revenue Growth With Product-led ExpansionDouble-digit growth across the company and particularly strong Trauma & Deformity performance indicate expanding procedure adoption and effective product launches. Raised revenue guidance supports the durability of demand, while new platforms and specialty products broaden future growth opportunities.
High Gross Margins And Improving Operating Cash EconomicsA stable 70%-plus gross margin provides a strong base for operating leverage as revenue scales. Record adjusted EBITDA and sharply improved cash flow suggest the business is moving toward self-funding, which could reduce reliance on external capital over time.
Bears Say
Persistent Net And Operating LossesDespite strong revenue and gross profit, OrthoPediatrics has not yet converted growth into GAAP profitability. Continued losses constrain internally funded expansion, weaken returns on equity and leave results sensitive to execution, scale benefits and the timing of new-product adoption.
Free Cash Flow Remains NegativePositive operating cash flow is encouraging, but ongoing negative free cash flow shows reinvestment and capital requirements still exceed internally generated funds. Until breakeven is sustained, the company may need to rely on cash reserves or debt to support growth.
High Investment And Execution Demands For GrowthGrowth depends on continued spending on instrument sets, sales capacity and personnel supporting clinic expansion. These investments can pressure cash conversion and margins if surgeon adoption, hospital purchasing or procedure volumes do not scale quickly enough.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $26.74 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $639.69M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Nov 03, 2026 which is in 68 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.002.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.23.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 26,109,789 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went up 6.849%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (12.24% Upside)
$27.50 (12.24% Upside)
Blogger Sentiment
Bullish
KIDS Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 254.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$27.50
▲(12.24% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―
Ownership Overview
32.84% Insiders
12.87% Mutual Funds
23.00% Other Institutional Investors
23.29% Public Companies and
Individual Investors